Aim: This study used proton magnetic resonance spectroscopy (1H MRS) to evaluate the neurochemistry of the frontal cortex in adolescents with symptoms of sleep and depression. Methods: Nineteen non-medicated adolescent boys (mean age 16.0 years; 9 clinical cases with depression/sleep symptoms and 10 healthy controls) underwent 1H MRS at 3 T. MR spectra were acquired from the anterior cingulate cortex (ACC), the dorsolateral prefrontal cortex, and frontal white matter. Concentrations of N-acetyl aspartate, total creatine, choline-containing compounds, total glutamine plus glutamate, and myo-inositol (mI) were compared in the 2 subgroups, and correlated with sleep and clinical measures in the total sample. Sleep was assessed with self-report questionnaires and ambulatory polysomnography recordings. Results: Concentrations of mI were lower in both frontal cortical regions among the depressed adolescents than in controls. No statistically significant differences in other metabolite concentrations were observed between the subgroups. Frontal cortex mI concentrations correlated negatively with depression severity, subjective daytime sleepiness, insomnia symptoms, and the level of anxiety, and correlated positively with total sleep time and overall psychosocial functioning. The correlations between mI in the ACC and total sleep time as well as daytime sleepiness remained statistically significant when depression severity was controlled in the analyses. Conclusion: Lower frontal cortex mI may indicate a disturbed second messenger system. Frontal cortical mI may thus be linked to the pathophysiology of depression and concomitant sleep symptoms among maturing adolescents. Short sleep and daytime sleepiness may be associated with frontal cortex mI independently from depression.

Keywords:
Myo-inositol, Polysomnography, Sleep, Sleepiness, Youth, Adolescent, Depression, Frontal cortex, Magnetic resonance spectroscopy, Magnetic resonance imaging
1.
Diagnostic and Statistical Manual of Mental Disorders DSM-IV. Washington DC, American Psychiatric Association, 1994.
2.
Barbe RP, Williamson DE, Bridge JA, Birmaher B, Dahl RE, Axelson DA, et al: Clinical differences between suicidal and nonsuicidal depressed children and adolescents. J Clin Psychiatry 2005;66:492-498.
3.
Liu X, Buysse DJ, Gentzler AL, Kiss E, Mayer L, Kapornai K, et al: Insomnia and hypersomnia associated with depressive phenomenology and comorbidity in childhood depression. Sleep 2007;30:83-90.
4.
Urrila AS, Karlsson L, Kiviruusu O, Pelkonen M, Strandholm T, Marttunen M: Sleep complaints among adolescent outpatients with major depressive disorder. Sleep Med 2012;13:816-823.
5.
Manglick M, Rajaratnam SM, Taffe J, Tonge B, Melvin G: Persistent sleep disturbance is associated with treatment response in adolescents with depression. Aust NZ J Psychiatry 2013;47:556-563.
6.
Urrila AS, Paunio T, Palomaki E, Marttunen M: Sleep in adolescent depression: physiological perspectives. Acta Physiol (Oxf) 2015;213:758-777.
7.
Kurth S, Ringli M, Geiger A, LeBourgeois M, Jenni OG, Huber R: Mapping of cortical activity in the first two decades of life: a high-density sleep electroencephalogram study. J Neurosci 2010;30:13211-13219.
8.
Buchmann A, Ringli M, Kurth S, Schaerer M, Geiger A, Jenni OG, et al: EEG sleep slow-wave activity as a mirror of cortical maturation. Cerebral Cortex 2011;21:607-615.
9.
Gogtay N, Giedd JN, Lusk L, Hayashi KM, Greenstein D, Vaituzis AC, et al: Dynamic mapping of human cortical development during childhood through early adulthood. Proc Natl Acad Sci USA 2004;101:8174-8179.
10.
Bourisly AK, El-Beltagi A, Cherian J, Gejo G, Al-Jazzaf A, Ismail M: A voxel-based morphometric magnetic resonance imaging study of the brain detects age-related gray matter volume changes in healthy subjects of 21-45 years old. Neuroradiol J 2015;28:450-459.
11.
Paus T, Keshavan M, Giedd JN: Why do many psychiatric disorders emerge during adolescence? Nature Rev Neurosci 2008;9:947-957.
12.
Pizzagalli DA: Frontocingulate dysfunction in depression: toward biomarkers of treatment response. Neuropsychopharmacology 2011;36:183-206.
13.
Hulvershorn LA, Cullen K, Anand A: Toward dysfunctional connectivity: a review of neuroimaging findings in pediatric major depressive disorder. Brain Imaging Behav 2011;5:307-328.
14.
Weber M, Webb CA, Deldonno SR, Kipman M, Schwab ZJ, Weiner MR, et al: Habitual “sleep credit” is associated with greater grey matter volume of the medial prefrontal cortex, higher emotional intelligence and better mental health. J Sleep Res 2013;22:527-534.
15.
Killgore WD, Schwab ZJ, Kipman M, DelDonno SR, Weber M: Voxel-based morphometric gray matter correlates of daytime sleepiness. Neurosci Lett 2012;518:10-13.
16.
Urrila AS, Artiges E, Massicotte J, Miranda R, Vulser H, Bézivin-Frere P, Lapidaire W, Lemaître H, Penttilä J, Conrod PJ, Garavan H, Paillère Martinot M-L, Martinot J-L; IMAGEN Consortium: Sleep habits, academic performance, and the adolescent brain structure. Sci Reports 2017;7:41678.
17.
Drummond SP, Brown GG, Stricker JL, Buxton RB, Wong EC, Gillin JC: Sleep deprivation-induced reduction in cortical functional response to serial subtraction. Neuroreport 1999;10:3745-3748.
18.
Horne JA: Human sleep, sleep loss and behaviour. Implications for the prefrontal cortex and psychiatric disorder. Br J Psychiatry 1993;162:413-419.
19.
Joo EY, Tae WS, Lee MJ, Kang JW, Park HS, Lee JY, et al: Reduced brain gray matter concentration in patients with obstructive sleep apnea syndrome. Sleep 2010;33:235-241.
20.
Altena E, Van Der Werf YD, Sanz-Arigita EJ, Voorn TA, Rombouts SA, Kuijer JP, et al: Prefrontal hypoactivation and recovery in insomnia. Sleep 2008;31:1271-1276.
21.
Altena E, Vrenken H, Van Der Werf YD, van den Heuvel OA, Van Someren EJ: Reduced orbitofrontal and parietal gray matter in chronic insomnia: a voxel-based morphometric study. Biol Psychiatry 2010;67:182-185.
22.
Steingard RJ, Yurgelun-Todd DA, Hennen J, Moore JC, Moore CM, Vakili K, et al: Increased orbitofrontal cortex levels of choline in depressed adolescents as detected by in vivo proton magnetic resonance spectroscopy. Biol Psychiatry 2000;48:1053-1061.
23.
Farchione TR, Moore GJ, Rosenberg DR: Proton magnetic resonance spectroscopic imaging in pediatric major depression. Biol Psychiatry 2002;52:86-92.
24.
Caetano SC, Fonseca M, Olvera RL, Nicoletti M, Hatch JP, Stanley JA, et al: Proton spectroscopy study of the left dorsolateral prefrontal cortex in pediatric depressed patients. Neurosci Lett 2005;384:321-326.
25.
Mirza Y, Tang J, Russell A, Banerjee SP, Bhandari R, Ivey J, et al: Reduced anterior cingulate cortex glutamatergic concentrations in childhood major depression. J Am Acad Child Adolesc Psychiatry 2004;43:341-348.
26.
Rosenberg DR, Macmaster FP, Mirza Y, Smith JM, Easter PC, Banerjee SP, et al: Reduced anterior cingulate glutamate in pediatric major depression: a magnetic resonance spectroscopy study. Biol Psychiatry 2005;58:700-704.
27.
Naismith SL, Lagopoulos J, Hermens DF, White D, Duffy SL, Robillard R, et al: Delayed circadian phase is linked to glutamatergic functions in young people with affective disorders: a proton magnetic resonance spectroscopy study. BMC Psychiatry 2014;14:345.
28.
Kaufman J, Birmaher B, Brent D, Rao U, Flynn C, Moreci P, et al: Schedule for Affective Disorders and Schizophrenia for School-Age Children - Present and Lifetime Version (K-SADS-PL): initial reliability and validity data. J Am Acad Child Adolesc Psychiatry 1997;36:980-988.
29.
Wentz E, Gillberg IC, Anckarsater H, Gillberg C, Rastam M: Adolescent-onset anorexia nervosa: 18-year outcome. Br J Psychiatry 2009;194:168-174.
30.
Ulberg R, Hersoug AG, Hoglend P: Treatment of adolescents with depression: the effect of transference interventions in a randomized controlled study of dynamic psychotherapy. Trials 2012;13:159.
31.
Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J: An inventory for measuring depression. Arch Gen Psychiatry 1961;4:561-71.
32.
Marton P, Churchard M, Kutcher S, Korenblum M: Diagnostic utility of the Beck Depression Inventory with adolescent psychiatric outpatients and inpatients. Can J Psychiatry 1991;36:428-431.
33.
Brooks SJ, Kutcher S: Diagnosis and measurement of adolescent depression: a review of commonly utilized instruments. J Child Adoles Psychopharmacology 2001;11:341-376.
34.
Hamilton M: A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62.
35.
Emslie GJ, Findling RL, Yeung PP, Kunz NR, Li Y: Venlafaxine ER for the treatment of pediatric subjects with depression: results of two placebo-controlled trials. J Am Acad Child Adolesc Psychiatry 2007;46:479-488.
36.
Mufson L, Dorta KP, Wickramaratne P, Nomura Y, Olfson M, Weissman MM: A Randomized effectiveness trial of interpersonal psychotherapy for depressed adolescents. Arch Gen Psychiatry 2004;61:577-584.
37.
Clarke G, Debar L, Lynch F, Powell J, Gale J, O'Connor E, et al: A randomized effectiveness trial of brief cognitive-behavioral therapy for depressed adolescents receiving antidepressant medication. J Am Acad Child Adolesc Psychiatry 2005;44:888-898.
38.
Saunders JB, Aasland OG, Babor TF, de la Fuente JR, Grant M: Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO Collaborative Project on Early Detection of Persons with Harmful Alcohol Consumption - II. Addiction 1993;88:791-804.
39.
Beck AT, Epstein N, Brown G, Steer RA: An inventory for measuring clinical anxiety: psychometric properties. J Consult Clin Psychology 1988;56:893-897.
40.
Soldatos CR, Dikeos DG, Paparrigopoulos TJ: Athens Insomnia Scale: validation of an instrument based on ICD-10 criteria. J Psychosom Res 2000;48:555-560.
41.
Drake C, Nickel C, Burduvali E, Roth T, Jefferson C, Pietro B: The pediatric daytime sleepiness scale (PDSS): sleep habits and school outcomes in middle-school children. Sleep 2003;26:455-458.
42.
Iber C, Ancoli-Israel S, Chesson AL, Quan SF: The AASM Manual for the Scoring of Sleep and Associated Events: Rules, Terminology and Technical Specifications. Westchester, American Academy of Sleep Medicine, 2007.
43.
Brand A, Richter-Landsberg C, Leibfritz D: Multinuclear NMR studies on the energy metabolism of glial and neuronal cells. Dev Neurosci 1993;15:289-298.
44.
Novak JE, Turner RS, Agranoff BW, Fisher SK: Differentiated human NT2-N neurons possess a high intracellular content of myo-inositol. J Neurochem 1999;72:1431-1440.
45.
Kim H, McGrath BM, Silverstone PH: A review of the possible relevance of inositol and the phosphatidylinositol second messenger system (PI-cycle) to psychiatric disorders - focus on magnetic resonance spectroscopy (MRS) studies. Human Psychopharmacol 2005;20:309-326.
46.
Rae CD: A guide to the metabolic pathways and function of metabolites observed in human brain 1H magnetic resonance spectra. Neurochem Res 2014;39:1-36.
47.
Spector R: Myo-inositol transport through the blood-brain barrier. Neurochem Res 1988;13:785-7.
48.
Gruber S, Frey R, Mlynarik V, Stadlbauer A, Heiden A, Kasper S, et al: Quantification of metabolic differences in the frontal brain of depressive patients and controls obtained by 1H-MRS at 3 Tesla. Invest Radiol 2003;38:403-8.
49.
Cross NE, Lagopoulos J, Duffy SL, Cockayne NL, Hickie IB, Lewis SJG, et al: Sleep quality in healthy older people: relationship with 1H magnetic resonance spectroscopy markers of glial and neuronal integrity. Behav Neurosci 2013;127:803-10.
50.
Poryazova R, Schnepf B, Werth E, Khatami R, Dydak U, Meier D, et al: Evidence for metabolic hypothalamo-amygdala dysfunction in narcolepsy. Sleep 2009;32:607-613.
51.
Voevodskaya O, Sundgren PC, Strandberg O, Zetterberg H, Minthon L, Blennow K, et al: Myo-inositol changes precede amyloid pathology and relate to ApoE genotype in Alzheimer disease. Neurology 2016;86:1754-1761.
52.
Sarchielli P, Presciutti O, Alberti A, Tarducci R, Gobbi G, Galletti F, et al: A 1H magnetic resonance spectroscopy study in patients with obstructive sleep apnea. Eur J Neurol 2008;15:1058-1064.
53.
Garnett MR, Blamire AM, Corkill RG, Cadoux-Hudson TA, Rajagopalan B, Styles P: Early proton magnetic resonance spectroscopy in normal-appearing brain correlates with outcome in patients following traumatic brain injury. Brain 2000;123:2046-2054.
54.
Tafazoli S, O'Neill J, Bejjani A, Ly R, Salamon N, McCracken JT, et al: 1H MRSI of middle frontal gyrus in pediatric ADHD. J Psychiatr Res 2013;47:505-512.
55.
Ortiz AE, Ortiz AG, Falcon C, Morer A, Plana MT, Bargallo N, et al: 1H-MRS of the anterior cingulate cortex in childhood and adolescent obsessive-compulsive disorder: a case-control study. Eur Neuropsychopharmacology 2015;25:60-68.
56.
Barkai AI, Dunner DL, Gross HA, Mayo P, Fieve RR: Reduced myo-inositol levels in cerebrospinal fluid from patients with affective disorder. Biol Psychiatry 1978;13:65-72.
57.
Shimon H, Agam G, Belmaker RH, Hyde TM, Kleinman JE: Reduced frontal cortex inositol levels in postmortem brain of suicide victims and patients with bipolar disorder. Am J Psychiatry 1997;154:1148-1150.
58.
Coupland NJ, Ogilvie CJ, Hegadoren KM, Seres P, Hanstock CC, Allen PS: Decreased prefrontal myo-inositol in major depressive disorder. Biol Psychiatry 2005;57:1526-1534.
59.
Jarnum H, Eskildsen SF, Steffensen EG, Lundbye-Christensen S, Simonsen CW, Thomsen IS, et al: Longitudinal MRI study of cortical thickness, perfusion, and metabolite levels in major depressive disorder. Acta Psychiatr Scand 2011;124:435-446.
60.
Chen L, Dai H, Dai Z, Xu C, Wu R: Anterior cingulate cortex and cerebellar hemisphere neurometabolite changes in depression treatment: A 1H magnetic resonance spectroscopy study. Psychiatry Clin Neurosci 2014;68:357-364.
61.
Davanzo P, Thomas MA, Yue K, Oshiro T, Belin T, Strober M, et al: Decreased anterior cingulate myo-inositol/creatine spectroscopy resonance with lithium treatment in children with bipolar disorder. Neuropsychopharmacology 2001;24:359-369.
62.
Auer DP, Putz B, Kraft E, Lipinski B, Schill J, Holsboer F: Reduced glutamate in the anterior cingulate cortex in depression: an in vivo proton magnetic resonance spectroscopy study. Biol Psychiatry 2000;47:305-313.
63.
Taylor MJ, Selvaraj S, Norbury R, Jezzard P, Cowen PJ: Normal glutamate but elevated myo-inositol in anterior cingulate cortex in recovered depressed patients. J Affect Disord 2009;119:186-189.
64.
Taylor MJ, Wilder H, Bhagwagar Z, Geddes J: Inositol for depressive disorders. Cochrane Database System Rev 2004;9:2.
65.
Gao F, Barker PB: Various MRS application tools for Alzheimer disease and mild cognitive impairment. Am J Neuroradiol 2014;35:S4-S11.
66.
Miller BL, Moats RA, Shonk T, Ernst T, Woolley S, Ross BD: Alzheimer disease: depiction of increased cerebral myo-inositol with proton MR spectroscopy. Radiology 1993;187:433-437.
67.
Fisher SK, Novak JE, Agranoff BW: Inositol and higher inositol phosphates in neural tissues: homeostasis, metabolism and functional significance. J Neurochem 2002;82:736-754.
68.
Maquet P: Brain mechanisms of sleep: contribution of neuroimaging techniques. J Psychopharmacol 1999;13:S25-S28.
69.
Yang XR, Langevin LM, Jaworska N, Kirton A, Lebel RM, Harris AD, et al: Proton spectroscopy study of the dorsolateral prefrontal cortex in youth with familial depression. Psychiatry Clin Neurosci 2016;70:269-77.
70.
Taylor M, Murphy SE, Selveraj S, Wylezinska M, Jezzard P, Cowen PJ, Evans J: Differential effects of citalopram and reboxetine on cortical Glx measured with proton MR spectroscopy. J Psychopharmacol 2008;22:473-476.
71.
Dzaja A, Arber S, Hislop J, Kerkhofs M, Kopp C, Pollmacher T, et al: Women's sleep in health and disease. J Psychiatr Res 2005;39:55-76.
72.
Rasgon NL, Thomas MA, Guze BH, Fairbanks LA, Yue K, Curran JG, et al: Menstrual cycle-related brain metabolite changes using 1H magnetic resonance spectroscopy in premenopausal women: a pilot study. Psychiatry Res 2001;106:47-57.
73.
Lenroot RK, Gogtay N, Greenstein DK, Wells EM, Wallace GL, Clasen LS, et al: exual dimorphism of brain developmental trajectories during childhood and adolescence. Neuroimage 2007;36:1065-1073.
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.